HK1209643A1 - Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut - Google Patents

Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut

Info

Publication number
HK1209643A1
HK1209643A1 HK15110575.5A HK15110575A HK1209643A1 HK 1209643 A1 HK1209643 A1 HK 1209643A1 HK 15110575 A HK15110575 A HK 15110575A HK 1209643 A1 HK1209643 A1 HK 1209643A1
Authority
HK
Hong Kong
Prior art keywords
biguanides
gut
preserving
peptides
integrity
Prior art date
Application number
HK15110575.5A
Other languages
English (en)
Chinese (zh)
Inventor
Roger R C New
Glen Travers
Original Assignee
Axcess Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcess Ltd filed Critical Axcess Ltd
Publication of HK1209643A1 publication Critical patent/HK1209643A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15110575.5A 2008-10-01 2015-10-27 Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut HK1209643A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0817969.9A GB0817969D0 (en) 2008-10-01 2008-10-01 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
HK1209643A1 true HK1209643A1 (en) 2016-04-08

Family

ID=40019875

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11109645.7A HK1155376A1 (en) 2008-10-01 2011-09-13 Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut
HK15110575.5A HK1209643A1 (en) 2008-10-01 2015-10-27 Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK11109645.7A HK1155376A1 (en) 2008-10-01 2011-09-13 Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut

Country Status (17)

Country Link
US (1) US9913850B2 (xx)
EP (2) EP2873420A1 (xx)
KR (1) KR101731656B1 (xx)
CN (1) CN102307582B (xx)
AU (1) AU2009299112B2 (xx)
CA (1) CA2740477C (xx)
DK (1) DK2361091T3 (xx)
ES (1) ES2535260T3 (xx)
GB (1) GB0817969D0 (xx)
HK (2) HK1155376A1 (xx)
IL (1) IL212050A (xx)
PL (1) PL2361091T3 (xx)
PT (1) PT2361091E (xx)
RU (1) RU2525290C2 (xx)
SI (1) SI2361091T1 (xx)
WO (1) WO2010037173A1 (xx)
ZA (1) ZA201102401B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101724431B1 (ko) 2015-08-19 2017-04-18 대우조선해양 주식회사 선박용 스러스터의 설치방법 및 이를 위한 얼라인먼트 결정용 지그
EP4281062A1 (en) * 2021-01-22 2023-11-29 AXCESS (UK) Ltd. Edta and egta for use in preserving the integrity of therapeutic compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US6156731A (en) * 1989-05-10 2000-12-05 G. D. Searle & Co. Polypeptide composition for oral administration
US5085864A (en) * 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
GB9013448D0 (en) * 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DK0640344T3 (da) * 1993-08-30 1999-07-05 Medichemie Ag Ursodesoxycholsyreholdigt lægemiddel i flydende administreringsform
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
WO1997021448A1 (en) * 1995-12-13 1997-06-19 Dullatur Limited A calcitonin preparation
DE19845403B4 (de) * 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB2355009A (en) * 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
WO2005110465A2 (en) * 2004-04-29 2005-11-24 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases
EP2248531A1 (en) 2004-08-03 2010-11-10 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
AU2006249869A1 (en) 2005-05-26 2006-11-30 Bristol-Myers Squibb Company N-terminally modified GLP-1 receptor modulators
AU2006288703B2 (en) * 2005-09-06 2011-09-22 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
WO2007032013A2 (en) * 2005-09-16 2007-03-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds for improving nutritional status, cognition and survival
GB0603252D0 (en) * 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
US8242294B2 (en) * 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods

Also Published As

Publication number Publication date
HK1155376A1 (en) 2012-05-18
ZA201102401B (en) 2011-11-30
KR20110128782A (ko) 2011-11-30
US20120035116A1 (en) 2012-02-09
CA2740477C (en) 2017-06-27
CN102307582A (zh) 2012-01-04
EP2361091B1 (en) 2015-01-21
AU2009299112A1 (en) 2010-04-08
CA2740477A1 (en) 2010-04-08
GB0817969D0 (en) 2008-11-05
EP2873420A1 (en) 2015-05-20
IL212050A (en) 2016-08-31
EP2361091A4 (en) 2012-05-23
CN102307582B (zh) 2015-10-07
SI2361091T1 (sl) 2015-07-31
ES2535260T3 (es) 2015-05-07
PT2361091E (pt) 2015-05-20
RU2011117267A (ru) 2012-11-10
AU2009299112B2 (en) 2013-09-26
DK2361091T3 (en) 2015-04-20
KR101731656B1 (ko) 2017-04-28
RU2525290C2 (ru) 2014-08-10
IL212050A0 (en) 2011-06-30
PL2361091T3 (pl) 2015-08-31
US9913850B2 (en) 2018-03-13
EP2361091A1 (en) 2011-08-31
WO2010037173A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
ZA201003681B (en) Compositions and methods comprising basic amino acid peptides and proteases
IL209176A0 (en) Amino acid sequences directed against cxcr4 and other gpcrs and compounds comprising the same
IL196205A (en) A device and method for preserving other grapes in their production
EP2196471A4 (en) PEPTIDE AND PROTEIN CONSERVATION PROCESS
ZA200807074B (en) 4-phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
HK1202436A1 (en) Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of cancer
IL190748A0 (en) Methods and compositions comprising non-natural amino acids
EP2170055A4 (en) COMPOSITION AND METHOD FOR TREATING BINDING WEAVE DAMAGE
IL248880B (en) Preparations containing r-g-cysteic acid peptides and their uses for the treatment of eye diseases
HK1160459A1 (en) Improved amino lipids and methods for the delivery of nucleic acids
EP2332859A4 (en) ARTICLE STORAGE DEVICE AND OPERATING METHOD THEREFOR
EP2180897A4 (en) PEPTIDE TYROSINASE INHIBITORS AND THEIR USES
IL195183A0 (en) Method for the extraction of one or several proteins present in milk
HK1161913A1 (en) Method for identifying allergenic proteins and peptides
EP2116481A4 (en) PACKAGING FOR HIGH PRESSURE TREATMENT AND HIGH PRESSURE PROCESSING METHOD FOR FOOD
EP2762011A4 (en) AMINO ACID-BASED SEASONING COMPOSITION COMPRISING L-GLUTAMIC ACID AND BASIC AMINO ACIDS
SG10201507362TA (en) Novel Regulatory Proteins And Inhibitors
EP1998790A4 (en) COMPOSITIONS COMPRISING PEPTIDES WITH NON-NATURAL AMINO ACIDS AND METHODS OF USE
EP2301951A4 (en) PEPTIDE DERIVATIVE AND COMPOSITION FOR PROMOTING TEAR SECRETION COMPRISING SAME
IL209595A0 (en) Variant hhip1 protein and methods and uses thereof
HK1209643A1 (en) Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut
EP2452690A4 (en) INHIBITORS OF THE PRODUCTION OF CARBOXYMETHYLARGININE AND COLLAGEN DISATING INHIBITOR
ZA201104160B (en) Crhr2 peptide agonists and uses thereof
EP2303910A4 (en) MULTIPLE LEU PEPTIDES AND THEIR ANALOGUES AS SELECTIVE PACE4 INHIBITORS AND EFFICIENT ANTIPROLIFERATIVE AGENTS
EP2273993A4 (en) METHODS AND COMPOSITIONS FOR INTRACERATEDBROVENTRICULAR FELBAMATE ADMINISTRATION